

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED**

**通用環球醫療集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code : 2666)**

### **UNAUDITED OPERATION SUMMARY OF THE GROUP FOR THE FIRST QUARTER OF 2026**

This announcement sets out the unaudited operation summary of Genertec Universal Medical Group Company Limited (the “**Company**” or “**Genertec Universal Medical**”), together with its subsidiaries (the “**Group**”), for the first quarter ended 31 March 2026.

This announcement is made pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

During the first quarter of 2026, the Group’s overall operation was stable and improving, with substantial progress in key areas. For the three months ended 31 March 2026, the revenue of the Group decreased by approximately 4.5% as compared with the corresponding period of 2025, primarily due to the decrease in financial business income, with the profit for the period increased by approximately 5.2% as compared with the corresponding period of 2025, mainly attributable to the optimization of funding cost control and the reduction of healthcare business costs, while the profit for the period attributable to ordinary shareholders increased by approximately 4.8% as compared with the corresponding period of 2025.

In respect of integrated healthcare business, the Group proactively responded to healthcare payment reforms, continuously strengthened the development of “Integration, Differentiation, Specialization, Digitalization and Optimization”, and steadily advanced the capability building of “Discipline Building, Scientific Research and Innovation, Talent Cultivation, Environment and Services Improvement”. The medical institutions affiliated with the Group performed well in the first quarter of 2026: during the quarter, the Group’s medical institutions added 3 new provincial-level key clinical specialties, bringing the total number of provincial-level and above key clinical specialties of the Group to 26; in terms of operations, through vigorously developing therapeutic outpatient services and non-medical insurance businesses, and deeply implementing all-year-round non-stop clinics, extended-

hour clinics and specialist clinics, outpatient and emergency visits in the first quarter increased against the trend by approximately 4.5% as compared with the corresponding period of 2025. The health check-up business delivered outstanding performance, with health check-up revenue increasing by approximately 13.3% year-on-year in the first quarter, further strengthening the supporting role of non-medical insurance businesses; based on the lean management concept, the Group continuously optimised the diagnosis and treatment service processes, deepened the management of advantageous disease types, and focused on high-value disease types to drive quality and efficiency improvements. The average length of hospital stay decreased to 8.9 days in the first quarter, and the output per bed increased by approximately 2.7% year-on-year, indicating a continuous improvement in operational efficiency; by deepening lean cost control, focusing on the management of pharmaceuticals and consumables, strengthening standardised disease type management, and precisely controlling diagnosis and treatment costs, the proportion of pharmaceutical and consumables costs to revenue decreased by 1.3 percentage points year-on-year, while the proportion of labour costs decreased by 3.2 percentage points year-on-year, further enhancing the Group's operational resilience.

In respect of specialised medical care and healthcare technology, the Group adheres to the “dual-wheel drive” of internal development and external expansion, cultivating its specialty businesses and core competencies. Currently, this segment has made continuous progress in areas such as business layout expansion and capability building, and the relevant merger and acquisition projects are also progressing smoothly. Genertec Universal Ophthalmology Beijing Flagship Hospital was officially put into operation, equipped with 20 beds and 47 pieces of internationally leading equipment. It will bring together nationally renowned experts, establish a consultation platform for complex ophthalmic diseases, and develop high-quality diagnosis and treatment plans for patients. The first Histotripsy liver cancer treatment in Chinese Mainland was successfully performed, marking a significant clinical advancement in the field of non-invasive tumour therapy in China. The public welfare initiative "Non-Invasive Hai Sheng Plan" was also launched simultaneously, aiming to make this globally advanced technology accessible to the general public. Genertec Universal Medical Technology Services (Tianjin) Co., Ltd. took the lead in releasing the industry's first group standard, the Medical Equipment Lifecycle Service Specification, and participated in the formulation of China's first national standard in the field of medical equipment operation and maintenance services. By fully integrating its practical experience accumulated from serving over 1,600 medical institutions nationwide into these standards, the company marks the official entry of medical equipment management services into a new stage of standardised and high-quality development supported by clear rules and standards, fully demonstrating the exemplary and leading role of central state-owned enterprises in standardization construction. The health digital and intelligent technology operation platform won the bid for the “Smart Haidian” project, which will cover two large tertiary hospitals in Haidian District, Beijing, while also supporting the access and expansion of other medical institutions at various levels within the district, injecting digital momentum into the development of “Healthy Haidian”.

In respect of finance business, the Group continues to focus on business areas such as medical health and elder care, equipment manufacturing, chemicals and pharmaceuticals, and specialty industries, solidly advancing the planning and implementation of the transformation and upgrading of the finance business, and actively exploring new models of industry-finance integration, including “finance lease + life cycle management of medical equipment”, “finance lease + elderly care operations”, “finance lease + supply chain finance”, and “finance lease + technology introduction + operations”, so as to serve the modern industrial system and the core responsibilities and main businesses of central state-owned enterprises with financial strength. The Group's subsidiary, Genertec Universal International Financial Leasing (Tianjin) Co., Ltd., successfully closed Tianjin's first RMB500 million strategic emerging ESG-linked syndicated loan. Meanwhile, the Group's wholly-owned subsidiary, Beijing Genertec E Chain Technology Co., Ltd., was officially established and inaugurated. As the only authorised supply chain finance platform under Genertec (GT-PRC), it empowers the coordinated

development of the industrial chains of central state-owned enterprises. As at 31 March 2026, the total interest-earning assets of the Group grew steadily as compared with the end of 2025, with net interest margin and net interest spread remaining stable as compared with the corresponding period of 2025. Asset quality remained stable and controllable overall, and provision coverage remained prudent.

The Company hereby reminds investors that the above unaudited operation summary for the first quarter ended 31 March 2026 was prepared based on the Group's internal figures and management accounts which have not been reviewed or audited by the auditors of the Group.

**Investors are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Genertec Universal Medical Group Company Limited**  
通用環球醫療集團有限公司  
**Chen Shisu**  
*Chairman of the Board*

Beijing, PRC, 29 April 2026

*As at the date of this announcement, the executive directors of the Company are Mr. Chen Shisu (Chairman), Mr. Xia Qi and Ms. Wang Lin; the non-executive directors of the Company are Mr. Tong Chaoyin, Mr. Lin Chunhai, Mr. Huang Youjie and Mr. Ma Wanming; and the independent non-executive directors of the Company are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas.*